Melanin-concentrating hormone (MCH) is a neuropeptide and its receptor is extensively expressed throughout the brain. MCH has been suggested to regulate the rewarding and reinforcing effects of psychostimulants by potentiating the dopaminergic system within the midbrain. Moreover, MCH and its receptor can regulate ERK activity. The present study investigated the role of MCH in the nucleus accumbens (NAc) in rats behaviourally sensitized to methamphetamine (Meth). We found that the development of Meth-induced locomotor sensitization was attenuated by MCH infused into the NAc shell but not core. Moreover, the elevation of ERK phosphorylation in the NAc shell induced by Meth was inhibited by locally infused MCH. Infusion of the MCH receptor 1 (MCHR1) antagonist SNAP 94847 into the NAc shell but not core augmented the initiation of locomotor sensitization and amplitude of elevated phosphorylated ERK levels induced by Meth. The expression of Meth-induced locomotor sensitization and ERK alterations after 1 wk withdrawal were not affected by either MCH or SNAP 94847 infused into the NAc shell or core. These results indicate that MCH in the NAc shell plays a critical role in the development but not expression of Meth-induced locomotor sensitization in rats, which might be mediated by the ERK signalling pathway. Our study suggests that MCH might be a potential target for the treatment of Meth addiction.
Introduction
Melanin-concentrating hormone (MCH) is a neuropeptide composed of 19 amino acids and is primarily separated from the salmon pituitary (Kawauchi et al., 1983) . MCH neurons are primarily located in the lateral hypothalamus (LH) and zona incerta (Bittencourt et al., 1992; Qu et al., 1996) and the MCH receptor (MCHR) is extensively expressed throughout the brain, including in the nucleus accumbens (NAc; Saito et al., 2001) . The MCHR has two subtypes, MCHR1 and MCHR2, that are seven-transmembrane domain G-protein-coupled receptors, but only MCHR 1 has been found in rodents (Bachner et al., 1999; Chambers et al., 1999; Lembo et al., 1999; Saito et al., 1999; Shimomura et al., 1999; Chung et al., 2009) . Previous studies suggested that MCH, as a type of neurotransmitter, may regulate behaviour, including food intake (Qu et al., 1996; Segal-Lieberman et al., 2006) , metabolism, arousal and reward (Chung et al., 2009; Gutierrez et al., 2011) . Moreover, increasing evidence indicates that MCH may participate in the development of many neural diseases. For example, a substantial loss of hypothalamic MCH neurons was found in patients with Parkinson's disease (Thannickal et al., 2007) . MCHR1 in the CA1 subfield of the hippocampus was shown to modulate depressive-like behaviour in rats (Garcia-Fuster et al., 2011) . Recently, the MCH system was shown to be involved in mediating alcohol reward and cue-induced alcohol relapse (Cippitelli et al., 2010) , suggesting that MCH might play a role in compulsive drug craving and relapse.
Locomotor sensitization induced by repeated psychostimulant exposure is an animal model widely used to investigate the mechanisms of compulsive drug craving and relapse Berridge, 1993, 2008; White et al., 1997; Xu et al., 2009) . Mesolimbic reward circuitry, mainly including dopamine transmission from the ventral tegmental area to NAc and other forebrain regions, plays a crucial role in psychostimulant-induced locomotor sensitization (Robinson and Becker, 1986; Robinson et al., 2001) . Much evidence has shown that neuroplasticity in the NAc mediates the development and expression of psychostimulant-induced locomotor sensitization (Robinson and Becker, 1986; Kalivas and Stewart, 1991) . Moreover, many signalling pathways in the NAc have been reported to be involved in the regulation of synaptic plasticity induced by methamphetamine (Meth). For example, ERK, a member of the mitogen-activated protein kinase (MAPK) signalling pathway family (Adams and Sweatt, 2002; Berman and Dudai, 2004) , is linked to dopamine D 1 receptors (Valjent et al., 2000; Zanassi et al., 2001; Mizoguchi et al., 2004) and participates in the rewarding effects of Meth (Mizoguchi et al., 2004) .
Accumulating studies have demonstrated that MCH and its receptors might interact with the dopamine system to modulate neural plasticity and behavioural plasticity induced by drugs of abuse. MCHR1 was shown to be co-expressed with dopamine D 1 and D 2 receptors in the NAc shell (Georgescu et al., 2005; Chung et al., 2009 ). MCHR1-deficient mice exhibited high sensitivity to Meth (Tyhon et al., 2008) and high D 1 and D 2 receptor binding capacity (Smith et al., 2005) . By potentiating the dopaminergic system in the NAc shell, MCHR1 was shown to play an important role in the modulation of cocaine reward (Chung et al., 2009) . Furthermore, other studies found that stimulation of MCH and MCHR1 regulates ERK activity (Pereira-da-Silva et al., 2005; Cook et al., 2008; Oh et al., 2010) . Previous research demonstrated that MAPK phosphorylation within the frontal cortex induced by D-amphetamine was significantly increased in MCHR1 −/− mice (Smith et al., 2008) . Interestingly, MCH was shown to activate ERK1/2 alone or synergistically with an adenylate cyclase activator, effects that were mediated by different pathways (Pissios et al., 2006) . Additionally, ERK activation in white adipose tissue might negatively regulate MCHinduced obesity and glucose intolerance (Pereirada-Silva et al., 2005) . Therefore, we hypothesized that MCH and MCHR1 in the NAc might mediate Meth-induced locomotor sensitization through ERK activity.
The present study investigated the role of MCH in the NAc in Meth-induced locomotor sensitization. More specifically, we examined (i) whether MCH or an MCHR1 inhibitor infused into the NAc shell and core affects the development and expression of Meth-induced locomotor sensitization and (ii) whether ERK activity in the NAc in rats behaviourally sensitized to Meth is affected by MCH or an MCHR1 inhibitor infused into the NAc shell and core.
Materials and method

Subjects
Male Sprague-Dawley rats, weighing 220-240 g upon arrival, were obtained from the Laboratory Animal Centre of Peking University Health Science Centre and housed in groups of five, with food and water freely available in the home cages. The rats were maintained on a reverse 12-h light/dark cycle (lights off 08:00 hours) with controlled temperature (23 ± 2°C) and humidity (50 ± 5%). All the animal procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Local Animal Care and Use Committee.
Drugs
Meth was obtained from the National Institute on Drug Dependence, Peking University (China) and dissolved in 0.9% saline. MCH was obtained from AnaSpec (USA) and dissolved in 0.9% saline. The MCHR1 antagonist N- [3-(1-[(4-[3,4-difluorophenoxy] phenyl)methyl]-4-piperidinyl)-4-methylphenyl]-2-methylpropanamide hydrochloride (SNAP 94847) was obtained from Tocris (USA) and dissolved in dimethyl sulfoxide according to our previous reports (Xu et al., 2009 (Xu et al., , 2011 . The drugs were freshly prepared before use and the doses were based on previous reports (Sanchez et al., 2001; Georgescu et al., 2005; Addy et al., 2007) .
Surgery
The rats (weighing 280-310 g) were anaesthetized with sodium pentobarbital (60 mg/kg i.p.) and bilaterally implanted with permanent guide cannulae (23 gauge; Plastics One, USA) 1 mm above the NAc core or shell. The cannulae were angled toward the midline at 16°. The brain coordinates were the following: NAc core (1.5 mm anterior to bregma, 3.8 mm lateral to midline, 6.0 mm ventral to flat skull surface, measured along the trajectory of the angled cannula); NAc shell (1.8 mm anterior to bregma, 3.2 mm lateral to midline, 6.6 mm ventral to flat skull surface (Zangen et al., 2006; Xu et al., 2009 Xu et al., , 2011 . Representative Nissl staining for the NAc core and shell is shown in Fig. 1 . The histology slides were obtained from naive rats that were micro-injected with 0.9% saline in the NAc core and shell. The rats were allowed to recover from surgery for 7 d.
Intracranial injections
MCH (2 μg/μl) and SNAP 94847 (30 μg/μl) were infused bilaterally into the NAc core or shell. A total volume of 0.5 μl was infused into each side for 1 min and the injector was kept in place for an additional 1 min to allow for diffusion (Lu et al., 2005 (Lu et al., , 2007 .
Tissue sample preparation
The procedure was similar to our previous reports (Li et al., 2008 (Li et al., , 2010 . Briefly, the rats were decapitated and their brains were quickly extracted, frozen in −60°C N-hexane and transferred to a freezer (−80°C). Using a freezing cryostat (−20°C; Reichert-Jung 2800 Frigocut E), bilateral tissue punches (16 gauge) of the NAc core or shell were taken from 1 mm thick coronal sections located approximately 2.2 mm from bregma. The tissue punches were homogenized (10-15 s × 3, 5 s intervals) with an electrical disperser (Wiggenhauser Sdn Bhd, Malaysia) after 30 min in RIPA lysis buffer (Beyotime Biotechnology, China) and then centrifuged at 10 000 g for 10 min. The procedures were performed at low temperature (0-4°C). The protein concentrations of the samples were determined using a bicinchoninic acid assay (Beyotime Biotechnology). The samples were further diluted in RIPA lysis buffer to equalize protein concentrations.
Western blot assays
The samples were treated according to our previous studies (Lu et al., 2003 (Lu et al., , 2005 Li et al., 2008 Li et al., , 2010 Cruz PI-1000; Vector Labs, USA). The band intensities for ERK1, ERK2, pERK1, pERK2 and β-actin were quantified by two observers who were blind to the experimental groups using Quantity One version 4.4.0 software (Bio-Rad, USA). The amount of the protein of interest in the samples was interpolated from the standard curve. Only the data for pERK and total ERK are presented because β-actin was not significantly different between any of the groups in the present study.
Behavioural sensitization
The experimental procedure for behavioural sensitization was performed according to our previous studies (Xu et al., 2009 (Xu et al., , 2011 , consisting of four phases: adaptation; induction; withdrawal; expression.
Adaptation phase
The rats were placed into the chambers for 2 h to monitor locomotor activity after daily injections of 0.9% saline (1 ml/kg i.p.) for 3 d. The level of locomotor activity on the last adaptation day (day 0) was defined as baseline.
Initiation phase
Locomotor activity was monitored for 2 h after a daily injection of 0.9% saline (1 ml/kg i.p.) or Meth (1 mg/kg i.p.) for 14 d. The experiments began at 08:00 hours and four series of training were conducted for 1 d.
Withdrawal phase
The rats were kept in their home cages for 7 d with food and water freely available.
Expression phase
After 7 d withdrawal in the home cage, locomotor activity was again monitored for 2 h following a single Meth challenge (1 mg/kg i.p.) to observe the expression of Meth-induced sensitization. The timing of the tests on the test day was same as the timing on the training days in each group of rats.
Locomotor activity test
Locomotor activity was measured with an automated video tracking system (DigBehv-LM4, Shanghai Jiliang Software Technology, China) that contained eight identical clear Plexiglas chambers (40 × 40 × 65 cm). The video files were analysed using DigBehv analysis software. Locomotor activity is expressed as the total distance (mm) travelled during a predetermined period of time (min).
Study design
Expt 1: effect of MCH in the NAc on the development of Meth-induced sensitization
To determine whether MCH in the NAc plays a role in the development of Meth-induced behavioural sensitization, we used eight groups of rats (n = 7-8 per group) which received bilateral microinjections of MCH (1 μg/side) or vehicle into the NAc shell or core 30 min before Meth (1 mg/kg i.p.) or 0.9% saline (1 ml/kg i.p.) injections every other day, followed by 2 h locomotor monitoring for 14 consecutive days (Fig. 2a) . To prevent brain destruction caused by excessive microinjections, MCH was not administered every day (Xu et al., 2009 (Xu et al., , 2011 . All the rats were decapitated after the last drug administration and their brains were extracted for the subsequent determination of ERK (phosphorylation and total) in the NAc shell and core by Western blot.
Expt 2: effect of MCH in the NAc on the expression of Meth-induced sensitization
To examine whether MCH in the NAc contributes to the expression of Meth-induced behavioural sensitization, eight groups of rats (n = 7-8 per group) received daily injections of Meth (1 mg/kg i.p.) or 0.9% saline (1 ml/kg i.p.), followed by 2 h locomotor activity monitoring for 14 consecutive days. After 7 d withdrawal from Meth in the home cages, all the rats were microinjected with MCH (1 μg/side) or vehicle into the NAc shell or core 30 min before a systemic challenge injection of Meth (1 mg/kg i.p.; Fig. 3a ). Two hours after the locomotor activity test, all the rats were decapitated and their brains were extracted for the subsequent determination of ERK in the NAc shell and core by Western blot.
Expt 3: effect of MCHR1 antagonist SNAP 94847 in the NAc on the development of Meth-induced sensitization
To determine whether MCH in the NAc plays a role in the development of Meth-induced behavioural sensitization, the rats were divided into eight groups (n = 7-8 per group) which received bilateral microinjections of the MCH1 receptor antagonist SNAP 94847 (15 μg/side) or vehicle into the NAc shell or core 60 min before Meth (1 mg/kg i.p.) or 0.9% saline (1 ml/ kg i.p.) injections every other day, followed by 2 h locomotor monitoring for 14 consecutive days (Fig. 4a ). All the rats were decapitated after the last drug administration and their brains were extracted for the subsequent determination of ERK in the NAc shell and core by Western blot.
Expt 4: effect of MCHR1 antagonist SNAP 94847 in the NAc on the expression of Meth-induced sensitization
To further examine whether MCH in the NAc contributes to the expression of Meth-induced behavioural sensitization, eight groups of rats (n = 7-8 per group) received daily injections of Meth (1 mg/kg i.p.) or 0.9% saline (1 ml/kg i.p.), followed by 2 h locomotor activity monitoring for 14 consecutive days. After 7 d withdrawal from Meth in the home cages, all the rats were microinjected with SNAP 94847 (15 μg/side) or vehicle into the NAc shell or core 60 min before a systemic challenge injection of Meth (1 mg/kg i.p.; Fig. 5a ). Two hours after locomotor activity monitoring, all the rats were decapitated and their brains were extracted for the subsequent determination of ERK in the NAc shell and core by Western blot.
Statistical analysis
The data are expressed as mean±S.E.M. and were analysed by analysis of variance (ANOVA). For the behavioural test data, repeated-measures ANOVA were conducted with treatment (Meth injection and MCH/ SNAP 94847 administration) as the between-subjects factor and test day (day 1, 4, 7, 10 and 14) and test significant. For clarity, significance in the post hoc analyses is indicated by symbols in the Figures.
Results
MCH microinjection into the NAc shell but not core attenuated the development of Meth-induced locomotor sensitization and ERK activity
In expt 1, rats were used to test the effect of MCH microinjected into NAc shell or core on the development of Meth-induced locomotor sensitization. Locomotor activity in rats treated with saline was not affected by MCH microinjected into the NAc shell or core (Fig. 2b, e Fig. 2e ). ANOVA of pERK levels revealed significant effects of Meth (F 1,20 = 10.71, p < 0.05) and MCH (F 1,20 = 4.61, p < 0.01) and a significant Meth × MCH interaction (F 1,20 = 8.11, p < 0.05; Fig. 2c ) in the NAc shell. The post hoc analysis showed that Meth increased pERK levels in the NAc shell (p < 0.05), which was blocked by MCH (p < 0.05). For the NAc core, no significant effects of Meth or MCH were found (p > 0.05; Fig. 2f ). Moreover, total ERK protein levels in the NAc shell and core were not significantly different between groups (p > 0.05; Fig. 2d, g ). Altogether, these results indicate that MCH microinjected into the NAc shell attenuated the development of Meth-induced locomotor activity and related ERK alterations.
MCH microinjection into the NAc shell and core did not affect the expression of Meth-induced locomotor sensitization or ERK activity
In expt 2 (Fig. 3) , rats were used to test the effect of MCH microinjection into the NAc shell or core on the expression of Meth-induced locomotor sensitization after 7 d withdrawal. ANOVA revealed a significant Meth × test day interaction (NAc shell, F 4,104 = 23.13, p < 0.05; NAc core, F 4,104 = 18.69, p < 0.05; Fig. 3b , e), indicating that rats which were injected with Meth exhibited the formation of locomotor sensitization. ANOVA revealed a significant effect of Meth (F 1,24 = 35.96, p < 0.05) but no significant effect of MCH (p > 0.05; Fig. 3c ) for MCH microinjection into the NAc shell and a significant effect of Meth (F 1,24 = 68.15, p < 0.05) but no significant effect of MCH (p > 0.05; Fig. 3f ) for MCH microinjection into the NAc core.
ANOVA of pERK levels revealed a significant effect of Meth (p < 0.05) but no significant effect of MCH (p > 0.05) for MCH microinjections into the NAc core and shell (Fig. 3d, g ). Moreover, no significant effect of Meth and MCH on total ERK levels was found in either the NAc shell or core among all the groups (p > 0.05). Altogether, these results indicate that MCH microinjected into the NAc core and shell did not affect the expression of Meth-induced locomotor sensitization or related ERK activity.
SNAP 94847 microinjection into the NAc shell but not core augmented the development of Meth-induced locomotor sensitization and ERK activity
In expt 3, rats were used to test the effect of the MCHR1 antagonist SNAP 94847 microinjected into NAc shell or core on the development of Meth-induced locomotor sensitization. Locomotor activity in rats treated with saline was not affected by SNAP 94847 microinjected into the NAc shell or core (Fig. 4b, e) . For SNAP 94847 microinjection into the NAc shell, ANOVA revealed significant effects of Meth (F 1,28 = 1191.00, p < 0.05) and SNAP 94847 (F 1,28 = 9.03, p < 0.05) and a significant Meth × SNAP 94847 × test day interaction (F 4,112 = 4.81, p < 0.05; Fig. 4b) . The post hoc analysis showed that SNAP 94847 microinjection into the NAc shell augmented the development of Meth-induced locomotor sensitization (p < 0.05). For SNAP 94847 microinjection into the NAc core, ANOVA revealed a significant effect of Meth (F 1,25 = 327.61, p < 0.05) but no significant effect of SNAP 94847 (p > 0.05) and no Meth × SNAP 94847 × test day interaction (p > 0.05; Fig. 4e) .
ANOVA of pERK levels revealed significant effects of Meth (F 1,17 = 34.12, p < 0.05) and SNAP 94847 (F 1,17 = 17.60, p < 0.05) and a significant Meth × SNAP 94847 interaction (F 1,17 = 11.97, p < 0.05; Fig. 4c ) in the NAc shell. The post hoc analysis showed that Meth increased pERK levels in the NAc shell (p < 0.05), which was enhanced by SNAP 94847 (p < 0.05). For the NAc core, no significant differences were found between groups (p > 0.05; Fig. 4f ). Moreover, total ERK protein levels in the NAc shell and core were not significantly affected in any of the groups (p > 0.05; Fig. 4d, g ). Altogether, these results indicate that SNAP 94847 microinjected into the NAc shell augmented the initiation of Meth-induced locomotor sensitization and related ERK activity.
SNAP 94847 microinjection into the NAc shell and core did not affect the expression of Meth-induced sensitization and ERK activity
In expt 4 (Fig. 5) , rats were used to test the effect of the MCHR1 antagonist SNAP 94847 microinjected into NAc shell or core on the expression of Meth-induced locomotor sensitization after 7 d withdrawal. ANOVA revealed a significant Meth × test day interaction (NAc shell, F 4,108 = 23.05, p < 0.05; NAc core, F 4,104 = 24.98, p < 0.05; Fig. 5b, e) , indicating that rats injected with Meth exhibited the formation of locomotor sensitization. For SNAP 94847 microinjection into the NAc shell, ANOVA revealed a significant effect of Meth (F 1,24 = 44.79, p < 0.05) but no significant effect of SNAP 94847 (p > 0.05) and no Meth × SNAP 94847 × test interval interaction (p > 0.05; Fig. 5c ). For SNAP 94847 microinjection into the NAc core, ANOVA revealed a significant effect of Meth (F 1,24 = 39.20, p < 0.05) but no significant effect of SNAP 94847 (p > 0.05) and no Meth × SNAP 94847 × test interval interaction (p > 0.05; Fig. 5f ).
ANOVA of pERK levels revealed a significant effect of Meth (F 1,19 = 16.41, p < 0.05) but no significant effect of SNAP 94847 (p > 0.05) in the NAc shell (Fig. 5d ) and no significant effect of Meth or SNAP 94847 (all p > 0.05) in the NAc core (Fig. 5g) . Moreover, total ERK levels in the NAc shell and core were not significantly different between groups (p > 0.05). Altogether, these results indicate that the MCHR1 antagonist SNAP 94847 microinjected into the NAc shell and core did not affect the expression of Meth-induced sensitization and related ERK activity.
Discussion
The present study indicated that MCH activity in the NAc shell but not core contributed to the development of Meth-induced behavioural sensitization. The main findings were: (i) development of Meth-induced locomotor sensitization was attenuated by MCH microinjected into the NAc shell but not core. Moreover, the elevation of pERK in the NAc shell induced by Meth was inhibited by locally infused MCH; (ii) microinjection of the MCHR1 antagonist SNAP 94847 into the NAc shell but not core augmented the initiation of locomotor sensitization and amplitude of elevated pERK levels induced by Meth; (iii) neither intra-NAc shell nor core microinjection of MCH or SNAP 94847 affected the expression of Meth-induced behavioural sensitization or pERK activity after 1 wk withdrawal.
MCH in the NAc shell regulates Meth-induced locomotor sensitization
Neuroadaptive alterations and sensitized molecular changes in the central nervous system, especially in NAc-related reward circuitry, have been shown to be involved in the drug-induced behavioural sensitization process (Robinson and Berridge, 1993; Fukakusa et al., 2008; Beutler et al., 2011) . The relatively more powerful pharmacological ability of Meth compared with cocaine and morphine to release dopamine may induce sensitization that is more dependent on adaptations in mesoaccumbens dopamine transmission (Vanderschuren and Kalivas, 2000) .
Medium spiny neurons in the NAc receive projections from MCH-containing neurons in the LH and may indirectly regulate MCH-containing neurons through glutamatergic neurons in the anterior LH (Sano and Yokoi, 2007) . Accumulating studies have demonstrated that MCH and MCHR1 are involved in synaptic plasticity. For example, the activity of N-methyl-D-aspartate (NMDA) was significantly deceased in CA1 pyramidal cells in the hippocampus in MCHR1
−/− mice (Adamantidis et al., 2005) and longterm potentiation was abolished in MCHR1 −/− mice compared with wild-type mice (Pachoud et al., 2010) .
In the present study, we found that increasing MCH activity by infusing MCH into the NAc shell attenuated the development of Meth-induced behavioural sensitization in rats. Additionally, the inhibition of MCH activity induced by the MCHR1 antagonist SNP94847 infused into the NAc shell augmented the development of Meth-induced behavioural sensitization in rats. One limitation of the present study is that we did not determine the possible dose-dependent effects of MCH or its antagonist on Meth-induced behavioural sensitization, which needs to be investigated in future research. Nevertheless, these findings indicated that MCH in the NAc shell plays a critical role in the development of Meth-induced behavioural sensitization.
MCH in the NAc shell may regulate Meth-induced locomotor sensitization via the ERK pathway
Psychostimulants activate many signalling pathways in the NAc and induce changes in the phosphorylation levels of several downstream molecules, such as cyclic adenosine monophosphate (cAMP)-regulated phosphoprotein 32, ERK, protein kinase A and cAMPresponse element binding protein (Nakayama et al., 2001; Brunzell et al., 2003; Hamada et al., 2004; Valjent et al., 2005) . Dopamine, one of the most important excitatory neurotransmitters that modulate the effects of psychostimulants, has recently been shown to regulate MCH by decreasing MCH neuron activity and release (Conductier et al., 2011) . γ-Aminobutyric acid (GABA), one of the most important inhibitory transmitters in the brain, also plays an important role in the acquisition of Meth-induced locomotor sensitization (Zhang et al., 2006) . Interestingly, MCH could inhibit the synaptic activity of glutamatergic and GABAergic LH neurons, suggesting that MCH might precisely modulate brain activity (Gao and van den Pol, 2001 ). Alterations in signalling pathways induced by synaptic adaptations of the central nervous system possibly indicate the mechanism by which Meth alters behaviour (Bennett et al., 1998; Hikida et al., 2010) . The present study showed that ERK activity in the NAc shell was elevated in rats behaviourally sensitized to Meth. The increase in ERK activity was blocked by MCH and augmented by an MCHR1 antagonist infused into the NAc shell but not core. A previous in vitro study showed that MCH played an important role in the regulation of ERK activity through MCHR (Pissios et al., 2006) . ERK has been shown to be critically involved in synaptic plasticity (Thomas and Huganir, 2004) and an ERK inhibitor prevented the rewarding effects of cocaine and even the long-lasting behavioural changes induced by cocaine (Valjent et al., 2000) . Alterations in ERK activity that mediate dopamine D 1 and NMDA glutamate receptor activation have been shown to contribute to the development of cocaine-induced behavioural sensitization (Valjent et al., 2010) . ERK has also been shown to participate in the enduring expression of cocaine-induced behavioural sensitization, even after protracted withdrawal from repeated cocaine exposure (Schumann and Yaka, 2009 ). Our results indicate that alterations in ERK activity in the NAc shell were associated with Meth-induced locomotor sensitization and persisted 1 wk after withdrawal. MCH may negatively regulate ERK activity in the NAc shell to prevent the locomotor effects of Meth in the development of Meth-induced behavioural sensitization. Nevertheless, ERK activity in the NAc shell was affected by neither MCH nor the MCHR1 antagonist in the expression of Meth-induced locomotor sensitization after prolonged withdrawal, indicating that MCH and MCHR1 in the NAc shell did not contribute to the persistence of Meth-induced behavioural sensitization.
MCH in the NAc shell but not core participates in the development of Meth-induced locomotor sensitization Interestingly, MCH administration into the NAc shell but not core affected the development of Meth-induced locomotor sensitization. This difference may be attributable to the markedly higher expression of MCHR in the NAc shell than core (Lembo et al., 1999; Borowsky et al., 2002) . Nevertheless, the NAc core also plays an important role in psychostimulant-induced behavioural sensitization. Our previous results demonstrated that glycogen synthase kinase 3β activity in the NAc core mediated both the development and expression of Meth-induced behavioural sensitization (Xu et al., 2011) . However, the present results might be explained by the specific roles of MCH and MCHR in the subdivisions of the NAc in behavioural sensitization. Neurons in the NAc shell express both dopamine D 1 and D 2 receptors, and their coordinated activation in the NAc shell is necessary to reinstate cocaine seeking in rats (Schmidt and Pierce, 2006) . Our findings are consistent with previous research that demonstrated differences in MCH expression between the NAc shell and core. For example, microinjection of an MCHR1 antagonist into the NAc shell but not core decreased food intake and resulted in the development of depressive-like symptoms (Georgescu et al., 2005) . Importantly, activation of the MCH system potentiates the dopamine system in the NAc shell (Chung et al., 2009) .
In summary, we demonstrated that MCH in the NAc shell but not core was involved in the development but not persistent expression of Meth-induced behavioural sensitization, and this involvement might be mediated by the ERK pathway. Our findings may have important implications for the understanding of the critical role of the MCH system in Meth-induced behavioural sensitization and suggest that MCH might be a potential target for the treatment of Meth addiction.
